Lurasidone hydrochloride CAS NO.367514-88-3

Details:

1. Lurasidone hydrochloride

2.White solid powder

3.assay no less than 99%

4.stock available

5.competitive price

Function:

   lurasidone characteristics of atypical antipsychotic drugs, the exact mechanisms in the treatment of schizophrenia like other atypical antipsychotics as not very clear, may be related to the dopamine D2 and serotonin (5-HT2A 5- 2A) on the antagonistic effect of receptor. For the treatment of schizophrenia, studies have reported lurasidone can improve cognitive function.
Adverse reaction: common adverse reactions are nausea, somnolence, sit not, Parkinson's disease and anxiety. Lurasidone no physical dependence. Lurasidone less cause weight gain, is not caused by glucose, lipid (Lei Zhi), change ECG and QT interval.
Contraindications: any known on ATUDA or the preparation of any of the components of hypersensitivity. At the same time, giving a strong CYP3A4 inhibitors such as [ketoconazole], ketoconazole and inducers such as rifampin, [rifampin].Cerebrovascular adverse reaction: antipsychotic use in atypical with dementia related psychosis in elderly patients treated had seen the incidence of cerebrovascular adverse events (such as increase, stroke, transient ischemic attack); neuroleptic malignant syndrome: immediate termination of treatment and close monitoring; tardive dyskinesia: such as clinical appropriate withdrawal; metabolic changes: atypical antipsychotics have accompanied by metabolic changes may increase cardiovascular / CEREBROVASCULAR risk. These metabolic changes including hyperglycemia, dyslipidemia, and weight gain.
Hyperglycemia and diabetes: monitoring in patients with hyperglycemia symptoms include polyuria, polydipsia, polyphagia, and weak. In patients with diabetes or at risk of diabetes in the regular monitoring of glucose.
Weight: weight gain recommendations once observed, clinical monitoring weight.